Examining the Link Between Depression and Seasonal Allergies

University of Maryland Baltimore (UMB)

Status: Completed

Conditions: Depression

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT00770068

R21MH075891 (U.S. NIH Grant/Contract)

DATR A2-AID

H26191

Details and patient eligibility

About

This study will examine whether spring and fall seasonal depression in individuals with high sensitivity to pollen is linked to seasonal increases in tree and ragweed pollen.

Full description

Those who suffer from depression have their normal lives interrupted by symptoms such as persistent sad thoughts, inability to feel pleasure, and potential suicide. Suicide and depression peak in the spring and fall. Worsening of depression, admission to a hospital for depression and bipolar depression, and use of electroconvulsive therapy for treatment of depression all peak in the spring. Although seasonal affective disorder (SAD), in which depression corresponds with seasonal changes, is commonly associated with the winter subtype, SAD is actually more prevalent as the spring subtype.

Allergies, which also peak in the spring and fall, have been linked to depression. Allergic reactions release cytokines, which are proteins that mediate the immune system response when a foreign substance enters the body. Previous studies have found both that an increase in cytokines in otherwise healthy individuals causes depressive symptoms and that cytokines cause the chemical tryptophan (TRP) to switch from producing serotonin, a neurotransmitter associated with feelings of well-being, to producing kynurenine (KYN), a potentially toxic chemical. To determine whether and to what extent allergies are linked to depression, this study will compare depression levels of participants with and without allergies before and during peak times for seasonal allergies. Results from this study may be used in further research to examine the effects of allergy prevention on depression.

Participants in this study will meet with researchers three times. At the first visit, they will be screened for allergies and give their demographic information. The timing of the second and third visits will depend on each participant's allergies. Those with spring allergies will be tested before and then during the spring allergy season. Those with fall allergies or with no allergies will be tested before and then during the fall allergy season. On the second and third visits questionnaires and clinical interviews will assess depression symptoms, and blood tests will be performed to measure chemical levels of cytokines, TRP, and KYN. During these visits participants will also be asked to complete a sleep log for 1 week. This will entail describing their sleep, activity, caffeine consumption, alcohol consumption, and use of sleep medications. A subgroup will wear an Actiwatch device, which electronically monitors sleep and wakefulness cycles, for 1 week, 24 hours a day.

Enrollment: 100 patients

Sex: All

Ages: 18 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of major depressive disorder or bipolar disorder

Exclusion criteria

• Pregnancy or intention to become pregnant within the duration of the study
• Dependence on alcohol, cocaine, stimulants, benzodiazepines, marijuana, or opiates
• Major medical illness, including cancer, hepatitis, and autoimmune disease
• A winter subtype of seasonal affective disorder
• Diagnosis of psychotic disorder
• Positive result in Phadiatop allergy test, but negative result in tree or ragweed pollen IgE test

Trial design

100 participants in 2 patient groups

Experimental group

Description:

All participants testing positive for tree and ragweed pollen allergies, as determined by levels of immunoglobulin E (IgE) antibodies

Control group

Description:

All participants testing negative for tree and ragweed pollen allergies, as determined by levels of IgE antibodies